Relevant detection indicator of prethrombotic state in patients with primary hypertension

doi:10.12998/wjcc.v11.i24.5678

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2288)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-8) series.

Item

Count

PDF

112

WORD

HTML

1086

Figures (1-1)

154

Tables (1-8)

240

Sum=1635

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

135

Download

432

Sum=567

Aug 26, 2023 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Aug 26, 2023; 11(24): 5678-5691
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5678

Table 1 Comparison of baseline data of participants in four groups

Baseline data		Grade 1 hypertension experimental group (n = 40)	Grade 2 hypertension experimental group (n = 40)	Grade 3 hypertension experimental group (n = 40)	Control group (n = 40)	Statistical values	P value
Age (yr)	< 60	31	29	30	28	χ² = 0.646	0.886
Age (yr)	≥ 60	9	11	10	12	χ² = 0.646	0.886
Sex	Male	28	25	23	25	χ² = 1.369	0.713
Sex	Female	12	15	17	15	χ² = 1.369	0.713
Combined diabetes	Yes	10	8	9	10	χ² = 0.387	0.946
Combined diabetes	No	30	32	31	30	χ² = 0.387	0.946
BMI (kg/m²)	≤ 24	15	14	15	13	χ² = 0.300	0.960
BMI (kg/m²)	> 24	25	26	25	27	χ² = 0.300	0.960
Smoking history	Yes	12	10	12	11	χ² = 0.340	0.952
Smoking history	No	28	30	28	29	χ² = 0.340	0.952
Drinking history	Yes	10	11	13	11	χ² = 0.587	0.899
Drinking history	No	30	29	27	29	χ² = 0.587	0.899
NYHA cardiac functional classification	Grade I	33	31	32	33	Z = 0.588	0.557
	Grade II	6	7	8	7
	Grade III	1	2	0	0
	Grade IV	0	0	0	0
Course of hypertension (mean ± SD, yr)		5.25 ± 2.15	5.35 ± 2.25	5.47 ± 2.17	-	F = 0.110	0.896

BMI: Body mass index; NYHA: New York Heart Association.

Table 2 Comparison of expression of relevant indicators of inflammation and vascular endothelial injury among the four groups (mean ± SD)

Group	Number of patients	hs-CRP (mmol/L)	TM (μg/L)
Grade 1 hypertension experimental group	40	2.05 ± 0.85	20.15 ± 1.05
Grade 2 hypertension experimental group	40	4.15 ± 1.05	22.85 ± 1.35
Grade 3 hypertension experimental group	40	5.45 ± 1.20	26.12 ± 2.25
Control group	40	1.72 ± 0.32	5.41 ± 1.20
F value	-	149.720	1420.213
P value	-	< 0.001	< 0.001

hs-CRP: High-sensitivity C-reactive protein; TM: Thrombomodulin.

Table 3 Comparison of hemorheological indexes among the four groups (mean ± SD)

Group	Number of cases	Hct (%)	ESR (mm/h)
Grade 1 hypertension experimental group	40	40.85 ± 3.15	30.25 ± 5.85
Grade 2 hypertension experimental group	40	41.25 ± 3.45	42.15 ± 6.25
Grade 3 hypertension experimental group	40	43.25 ± 4.25	60.15 ± 8.15
Control group	40	39.56 ± 2.85	25.12 ± 5.05
F value	-	7.810	234.107
P value	-	< 0.001	< 0.001

Hct: Hematocrit; ESR: Erythrocyte sedimentation rate,

Table 4 Comparison of platelet-related indicators among the four groups (mean ± SD)

Group	Number of patients	CD62P (%)	PLT (× 10⁹)
Grade 1 hypertension experimental group	40	8.85 ± 1.18	115.68 ± 40.15
Grade 2 hypertension experimental group	40	11.12 ± 1.35	108.56 ± 35.85
Grade 3 hypertension experimental group	40	13.10 ± 1.75	95.25 ± 30.12
Control group	40	6.25 ± 1.05	135.25 ± 50.12
F value	-	190.280	7.052
P value	-	< 0.001	< 0.001

CD62P: P-selectin on platelet surface; PLT: Platelet count.

Table 5 Comparison of coagulation related indicators among the four groups (mean ± SD)

Group	Number of patients	APTT (s)	PT (s)	TT (s)	FIB (g/L)
Grade 1 hypertension experimental group	40	29.25 ± 2.71^b	11.98 ± 0.50^b	15.95 ± 1.08^b	3.20 ± 0.51^b
Grade 2 hypertension experimental group	40	27.25 ± 2.24^a	10.82 ± 0.92^a	15.01 ± 0.89^a	5.12 ± 0.68^a
Grade 3 hypertension experimental group	40	25.42 ± 1.52^a	10.02 ± 0.34^a	14.02 ± 0.65^a	6.19 ± 1.15^a
Control group	40	30.12 ± 2.65	12.31 ± 0.52	16.08 ± 1.12	3.01 ± 0.42
F value	-	315.25	105.522	174.218	82.151
P value	-	< 0.001	< 0.001	< 0.001	< 0.001

^aP < 0.05.

^bP > 0.05 vs control group.

APTT: Activated partial thromboplastin time; PT: Prothrombin; TT: Plasma thrombin time; FIB: Fibrinogen.

Table 6 Logistic regression analysis of the above indicators and prethrombotic state of primary hypertension

Variable	B	SE	Wals	P value	OR value	95%CI
Variable	B	SE	Wals	P value	OR value	Upper limit	Lower limit
Constant	-2.717	0.665	16.720	< 0.001	0.066	-	-
hs-CRP	1.535	0.307	25.086	< 0.001	4.643	2.546	8.468
TM	0.684	0.248	7.584	0.006	1.982	1.218	3.226
Hct	0.184	0.058	10.219	0.001	1.202	1.074	1.346
ESR	0.226	0.042	29.282	< 0.001	1.254	1.155	1.361
CD62P	2.261	0.486	21.684	< 0.001	9.592	3.704	24.842
PLT	0.017	0.005	12.958	< 0.001	1.017	1.008	1.027
APTT	0.716	0.128	11.664	< 0.001	1.926	1.421	2.158
PT	0.805	0.148	15.660	< 0.001	2.192	1.605	2.840
TT	0.924	0.108	13.348	< 0.001	2.490	1.808	3.418
FIB	5.212	0.863	19.566	< 0.001	88.423	18.137	427.013

hs-CRP: High-sensitivity C-reactive protein; TM: Thrombomodulin; Hct: Hematocrit; ESR: Erythrocyte sedimentation rate; CD62P: P-selectin on platelet surface; PLT: Platelet count; APTT: Activated partial thromboplastin time; PT: Prothrombin; TT: Plasma thrombin time; FIB: Fibrinogen.

Table 7 Efficacy analysis of each indicator in predicting primary hypertension

Indicator	AUC	95%CI for AUC	Standard error	P value	Cut-off value	Sensitivity	Specificity
hs-CRP	0.890	0.840-0.941	0.026	< 0.001	1.135	0.950	0.975
TM	0.989	0.972-1.000	0.009	< 0.001	18.345	0.992	0.05
Hct	0.676	0.586-0.766	0.046	0.001	34.990	0.967	0.975
ESR	0.911	0.867-0.955	0.022	< 0.001	17.365	0.992	0.975
CD62P	0.982	0.966-0.997	0.008	< 0.001	6.635	0.992	0.325
PLT	0.680	0.572-0.788	0.055	0.001	47.290	0.975	0.975
APTT	0.987	0.973-1.000	0.007	< 0.001	38.650	0.992	0.650
PT	0.942	0.908-0.975	0.017	< 0.001	12.810	0.992	0.875
TT	0.929	0.890-0.968	0.020	< 0.001	12.680	0.992	0.975
FIB	0.957	0.929-0.986	0.015	< 0.001	2.110	0.975	0.267

AUC: Area under the curve; hs-CRP: High-sensitivity C-reactive protein; TM: Thrombomodulin; Hct: Hematocrit; ESR: Erythrocyte sedimentation rate; CD62P: P-selectin on platelet surface; PLT: Platelet count; APTT: Activated partial thromboplastin time; PT: Prothrombin; TT: Plasma thrombin time; FIB: Fibrinogen.

Table 8 Efficacy analysis of each indicator in predicting primary hypertension

Indicator	hs-CRP	TM	Hct	ESR	CD62P	PLT	APTT	PT	TT	FIB
hs-CRP	-	0.792^a	0.237 (0.003)	0.782^a	0.753^a	-0.296^a	-0.794^a	-0.652^a	-0.631^a	0.802^a
TM	0.792^a	-	0.300^a	0.818^a	0.813^a	-0.329^a	-0.856^a	-0.734^a	-0.682^a	0.846^a
Hct	0.237 (0.003)	0.300^a	-	0.317^a	0.279^a	-0.113 (0.153)	-0.295^a	-0.201 (0.011)	-0.279^a	0.318^a
ESR	0.782^a	0.818^a	0.317^a	-	0.788^a	-0.267 (0.001)	-0.821^a	-0.665^a	-0.626^a	0.830^a
CD62P	0.753^a	0.813^a	0.279^a	0.788^a	-	-0.246 (0.002)	-0.850^a	-0.707^a	-0.668^a	0.814^a
PLT	-0.296^a	-0.329^a	-0.113 (0.153)	-0.267 (0.001)	-0.246 (0.002)	-	0.331^a	0.214 (0.007)	0.223 (0.005)	-0.272 (0.001)
APTT	0.794^a	0.856^a	0.295^a	0.821^a	0.850^a	-0.331	-	0.677^a	0.681^a	-0.843^a
PT	0.652^a	0.734^a	0.201 (0.011)	0.665^a	0.707^a	-0.214 (0.007)	0.677^a	-	0.534^a	-0.739^a
TT	0.631^a	0.682^a	0.279^a	0.626^a	0.668^a	-0.223 (0.005)	0.681^a	0.534^a	-	-0.674^a
FIB	0.802^a	0.846^a	0.318^a	0.830^a	0.814^a	-0.272 (0.001)	-0.843^a	-0.739^a	-0.674^a	-

^aP < 0.05.

Citation: Luo J, Yang T, Ding L, Xiong JH, Ying T, Xu F. Relevant detection indicator of prethrombotic state in patients with primary hypertension. World J Clin Cases 2023; 11(24): 5678-5691
URL: https://www.wjgnet.com/2307-8960/full/v11/i24/5678.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i24.5678